Studies have shown that the role of hsa-miR-623 as a tumor suppressor has been confirmed, such as targeting the effect of XRCC5 to inhibit the proliferation and metastasis of cancer cells such as breast cancer and liver cancer [49], inhibit the proliferation of gastric cancer cells, and increase the drug sensitivity of 5-fluorouracil by targeting cyclin D1 [50]. Here, XRCC5 is linked to breast carcinoma.